3-V Biosciences, Inc. Presents at Windhover's Therapeutic Area Partnerships Conference, Nov-29-2012 03:20 PM. Venue: Westin Copley Place, Boston, Massachusetts, United States.

3-V Biosciences, Inc. announced that preclinical data for its novel fatty acid synthase (FASN) inhibitors for the treatment of chronic hepatitis C virus (HCV) infection will be presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases being held November 9-13 in Boston, Massachusetts. The company's FASN inhibitors for the treatment of HCV are designed to have broad-spectrum activity, a high barrier to resistance and the ability to combine with direct-acting antivirals, such as nucleotide/nucleoside inhibitors, protease inhibitors, NS5a inhibitors and other mechanisms of action currently in development. Data characterizing the preclinical antiviral activity of 3-V's FASN inhibitors will be featured in oral and poster presentations during The Liver Meeting. Highlights of these data include: Orally bioavailable representative molecules are potent and specific, with IC50s in the 5-50nM range; Inhibitors have demonstrated excellent exposure and low toxicity in rodents associated with prolonged in vivo suppression of FASN; Antiviral activity against wild-type Genotype 1a, 1b and 2a replicons; and Antiviral activity against mutant HCV replicons resistant to NS3, NS4b, NS5a and NS5b inhibitors. The company's FASN inhibitors are a chemically diverse set of potent, specific, reversible molecules with an excellent range of pharmaceutical properties. The company has filed multiple worldwide patent applications covering these inhibitors. 3-V's HCV program is on track for an IND in the first quarter of 2013 and the company anticipates clinical proof-of-concept data by year-end 2013.

3-V Biosciences, Inc. announced the appointment of Douglas Buckley, PhD, as Vice President of Biology. Dr. Buckley brings more than 25 years of experience in the biopharmaceutical industry, and his discoveries and research leadership have resulted in several marketed products and many more in clinical development. Dr. Buckley joins 3-V from Exelixis, Inc., where he served most recently as Vice President of Biochemistry. In that role, he led research and discovery teams responsible for delivering over thirty IND-ready compounds to Exelixis' internal pipeline and to external partnerships.